ALNY•benzinga•
Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga